Silexion Therapeutics Corp
For the period ended Jun 30, 2024. Filed Aug 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 29, 2024
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
| June 30, | December 31 | |
|---|---|---|
| 2024 | 2023 | |
| U.S. dollars in thousands | ||
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $1,697 | $4,595 |
| Restricted cash | 25 | 25 |
| Prepaid expenses | 527 | 335 |
| Other current assets | 66 | 24 |
| TOTAL CURRENT ASSETS | 2,315 | 4,979 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 25 | 25 |
| Long-term deposit | 5 | 5 |
| Property and equipment, net | 40 | 49 |
| Operating lease right-of-use asset | 140 | 198 |
| TOTAL NON-CURRENT ASSETS | 210 | 277 |
| TOTAL ASSETS | $2,525 | $5,256 |
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31 | |
|---|---|---|
| 2024 | 2023 | |
| U.S. dollars in thousands | ||
| Liabilities and redeemable convertible preferred shares, net of capital deficiency | ||
| CURRENT LIABILITIES: | ||
| Trade payables | $281 | $319 |
| Current maturities of operating lease liability | 108 | 112 |
| Warrants to preferred shares (including $321 and $186 due to related party, as of June 30, 2024 and December 31, 2023, respectively) | 345 | 200 |
| Employee related obligations | 251 | 207 |
| Accrued expenses and other account payable | 1,379 | 1,358 |
| TOTAL CURRENT LIABILITIES | 2,364 | 2,196 |
| NON-CURRENT LIABILITIES: | ||
| Long-term operating lease liability | 8 | 59 |
| TOTAL NON-CURRENT LIABILITIES | $8 | $59 |
| TOTAL LIABILITIES | $2,372 | $2,255 |
| COMMITMENTS AND CONTINGENT LIABILITIES | ||
| REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS: | ||
| Convertible Series A Preferred Shares (NIS 0.01 par value, 510,000 shares authorized as of June 30, 2024 and December 31, 2023, 388,088 shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $8,162 as of June 30, 2024; | ||
| Convertible Series A-1 Preferred Shares (NIS 0.01 par value per share, 120,000 shares authorized as of June 30, 2024 and December 31, 2023, 91,216 shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $2,443 as of June 30, 2024; | ||
| Convertible Series A-2 Preferred Shares (NIS 0.01 par value per share, 200,000 shares authorized as of June 30, 2024 and December 31, 2023, 45,458 shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $2,763 as of June 30, 2024; | ||
| Convertible Series A-3 Preferred Shares (NIS 0.01 par value per share, 80,000 shares authorized as of June 30, 2024 and December 31, 2023, 63,331 shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $2,887 as of June 30, 2024; | ||
| Convertible Series A-4 Preferred Shares (NIS 0.01 par value per share, 815,000 shares authorized as of June 30, 2024 and December 31, 2023, 21,717* shares issued and outstanding as of June 30, 2024 and December 31, 2023); aggregate liquidation preference of $1,076 as of June 30, 2024; | ||
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES | 15,057 | 15,057 |
| CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS | 3,353 | 3,420 |
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS | $18,410 | $18,477 |
| CAPITAL DEFICIENCY: | ||
| Ordinary shares (NIS 0.01 par value per share, 3,275,000 shares authorized as of June 30, 2024 and December 31, 2023; 250,492 and 219,354 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively) | 1 | 1 |
| Additional paid-in capital | 11,398 | 11,334 |
| Accumulated deficit | (29,656) | (26,811) |
| TOTAL CAPITAL DEFICIENCY | $(18,257) | $(15,476) |
| TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY | $153 | $3,001 |
| TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY | $2,525 | $5,256 |
| * | Net of 121,119 treasury shares held by the subsidiary as of June 30, 2024 and December 31, 2023 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.